Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$4.20 USD

4.20
1,293,958

+0.14 (3.45%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $4.21 +0.01 (0.24%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for AGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Agenus Inc. [AGEN]

Reports for Purchase

Showing records 1 - 20 ( 281 total )

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

01/15/2026

Company Report

Pages: 5

Zydus Deal Clears Regulatory Review; Takeaways from Our Meeting With Management at JPM

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/11/2025

Company Report

Pages: 6

3Q25 Recap: Phase 3 BATTMAN on Track for 4Q25 Initiation; IIT Data Updates in 1H26

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

10/17/2025

Company Report

Pages: 5

Bot/Bal OS Curve Tail Indicates Long-Term Survival in Multiple Solid Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

09/10/2025

Company Report

Pages: 4

Bot/Bal Compassionate Use Authorized for MSS-CRC in France; Takeaways From Our Fireside Chat

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/28/2025

Company Report

Pages: 4

Our Takeaways From Management''s Stakeholder Briefing; Phase 3 BATTMAN on Track For 4Q25

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/12/2025

Company Report

Pages: 6

2Q25 Recap: BATTMAN Trial Set to Intiate 4Q25; Additional Bot/Bal Data to Come 2H25

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

07/08/2025

Company Report

Pages: 5

Additional Phase 1 Data Highlight Bot/Bal Efficacy in 3L

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

06/04/2025

Company Report

Pages: 6

Sale of CMC Facilities to Zydus + Equity Investment Alleviates Cash Overhang

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/13/2025

Company Report

Pages: 5

1Q25 Recap: Bot/Bal Regulatory Interactions for Metastatic CRC to Resume

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

04/30/2025

Company Report

Pages: 4

NEOASIS Data at AACR Demonstrate Bot/Bal Neoadjuvant Benefit in Multiple Solid Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/18/2025

Company Report

Pages: 4

Model Update Following 10-K Filing; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/12/2025

Company Report

Pages: 4

4Q24 Recap: Cost Reductions Take Center Stage

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

01/27/2025

Company Report

Pages: 7

New Data From Bot/Bal Presentations at ASCO-GI

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

01/22/2025

Company Report

Pages: 5

ASCO-GI Abstract Takeaways; Neoadjuvant Bot + Bal Data Remain Consistent in More Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/22/2025

Industry Report

Pages: 74

Innovation, Optimism, and Opportunity: Critical Themes for Biotech Investors

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 150.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

01/17/2025

Industry Report

Pages: 11

JPM Meeting Takeaways

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/05/2024

Company Report

Pages: 5

Model Update to Reflect Planned Cost Reductions

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/27/2024

Company Report

Pages: 5

CRC Prioritized for Near-Term Development; $22M Mortgage Secured

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/04/2024

Industry Report

Pages: 14

Deep Dive Into TIGIT-Based Therapies; Awaiting GALAXIES Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 50.00

Research Provided by a Third Party

Company: Agenus Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

08/08/2024

Company Report

Pages: 6

2Q24 Recap: Data for Bot/Bal in Pancreatic and Melanoma Expected in 2H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party